Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Beijing, Xicheng District, China Clinical Trials

A listing of Beijing, Xicheng District, China clinical trials actively recruiting patients volunteers.

RESULTS

Found (56) clinical trials

Safety Efficacy and Pharmacokinetic of BPI-9016M in Patients With c-Met- Dysregulated Advanced NSCLC

The main objective of this study is to evaluate the safety, tolerability, efficacy and pharmacokinetics of BPI-9016M in patients with c-Met-dysregulated advanced NSCLC.Biomarkers related to the efficacy of BPI-9016M will be investigated.

Phase

0.49 miles

Learn More »

Clinical Study on Anti-tumor Effect Induced by Activated Primary Natural Killer NK Cells

This study will analyze and evaluate the following items: The safety of natural killerNK cells for treatment of subjects with solid tumors. Forty patients will be enrolled for each of the five cancers (in total 200 patients will be enrolled). The effectiveness of natural killerNKcell therapy alone or with chemotherapy ...

Phase

1.68 miles

Learn More »

Study of S-1 Plus DC-CIK for Patients With Unresectable Locally Advanced Pancreatic Cancer

The purpose of this study is to evaluate the antitumor effect and safety of clinical effectiveness S-1 plus dendritic cell activated Cytokine induced killer treatment (DC-CIK) for unresectable locally advanced pancreatic cancer.

Phase

2.13 miles

Learn More »

Combination of Immunotherapy and Hyperthermia in Advanced Malignant Mesothelioma

The purpose of this study is to investigate the clinical efficacy and toxicity of anti-PD-1 monoclonal antibody plus autologous dendritic cells-cytokine induced killer cell (DC-CIK) immunotherapy combined with hyperthermia in advanced malignant mesothelioma patients.Furthermore,to characterize response to therapy,the investigators intent to explore the predictive biomarker for this regimen.

Phase

2.13 miles

Learn More »

Anti-PD-1 Alone or Combined With Autologous Cell Therapy in Advanced NSCLC

A randomized controlled study to compared the clinical effects and safety of immunotherapy with dendritic cells and cytokine-induced killer cells administered with anti-PD-1 antibody in advanced NSCLC.

Phase

2.13 miles

Learn More »

Anti-PD-1 Alone or Combined With Autologous DC-CIK Cell Therapy in Advanced Solid Tumors

The purpose of this study is to compare the clinical efficacy and toxicity of anti-PD-1 monoclonal antibody alone with anti-PD-1 monoclonal antibody plus autologous dendritic cells-cytokine induced killer cell (DC-CIK) immunotherapy in advanced tumor patients.Furthermore,to characterize response to therapy we intent to evaluate the role of cell-free DNA (cfDNA) and ...

Phase

2.13 miles

Learn More »

Hyperthermia Combined With Immunotherapy in the Treatment of Abdominal and Pelvic Malignancies or Metastases

It is a non-randomized pilot study.The allocation will be determined by patients or their immediate family members who were cooperative with physician's interpretations on the disease progression and updated information of cutting of edge treatment, the financial affordability, availability of treatment plans, possible tolerance or risks etc.The purpose of this ...

Phase

2.13 miles

Learn More »

Immunotherapy of Gastric Cancer With Autologous Tumor Derived Heat Shock Protein gp96

The purpose of this study is to evaluate the safety and effectiveness of autologous gp96 treatment of gastric cancer.

Phase

2.27 miles

Learn More »

Safety and Efficacy Evaluation of IM19 CAR-T Cells

Assessment of the Safety and Feasibility of Administering T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor to Patients With CD19+ B-cell leukemia or CD19+ B-ALL patients and determine the MTD,LTD and the best dosage.

Phase

2.27 miles

Learn More »

Two Stage Study of Combination of Chemotherapy SHR-1210 and/or Decitabine for Relapsed/Refractory PMBCLs

This is a two stage, Phase I/II clinical trial for patients with relapsed or refractory primary mediastinal large B-cell lymphoma (rrPMBCL). In the first stage, the participants will receive GVD (Gemcitabine, Vinorelbine and Doxorubicine) chemotherapy and PD-1 antibody (SHR-1210) treatment. The safety and efficacy of combined regimen will be evaluated. ...

Phase

2.27 miles

Learn More »